久久亚洲国产成人影院-久久亚洲国产的中文-久久亚洲国产高清-久久亚洲国产精品-亚洲图片偷拍自拍-亚洲图色视频

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Companies

World-first drug to be launched in China

By Liu Zhihua | chinadaily.com.cn | Updated: 2018-12-19 13:36
Share
Share - WeChat
A worker leaves the AstraZeneca research facility in Loughborough, the United Kingdom. [Photo/Agencies]

AstraZeneca China announced on Tuesday that new anemia drug roxadustat has received approval from the National Medical Products Administration.

The drug was developed in collaboration with FibroGen China.

China has become the first country worldwide to approve the oral anemia treatment hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI).

AstraZeneca said the drug was expected to be launched in China during the second half of 2019.

Roxadustat, Chinese brand name Ai Rui Zhuo(愛瑞卓), has achieved three primary breakthroughs: it's the first drug to the adopt the HIF mechanism; the first of its kind developed and incubated in China, and the first approved in China before any other market globally, the company said.

FibroGen China was responsible for the clinical trials and registration of roxadustat in China, and now holds the certificate of drug registration issued by the NMPA.

Following the approval, FibroGen China will manage manufacturing, medical affairs and distribution.

AstraZeneca will manage its launch and commercialization.

According to the NMPA approval, roxadustat is to be used in the treatment of anemia caused by chronic kidney disease (CKD) in patients who are dialysis-dependent (DD).The medicine can be prescribed to patients who use hemodialysis or peritoneal dialysis.

There are over 120 million CKD patients in China, and anemia is one of the complications of CKD, occurring at a rate of up to 98.2 percent in patients on dialysis, according to medical journals Lancet and Chinese Journal of Nephrology.

If anemia is not controlled, it increases cardiovascular risks, as well as mortality in patients on dialysis, and may affect patients' mental health and social functions, imposing a heavy burden on patients, their families and society.

According to clinical data in China, roxadustat can effectively increase and keep hemoglobin in dialysis patients with anemia caused by CKD, AstraZeneca said.

The development of roxadustat ends a long period in which there were no new drugs developed by a new mechanism for the treatment of CKD-caused anemia, said Chen Xiangmei, member of the Chinese Academy of Engineering and head of the PLA Institute of Kidney Diseases.

AstraZeneca also attributed the fast approval to the Chinese government's efforts in supporting pharmaceutical innovation and providing more quality new drugs to Chinese patients.

Leon Wang, executive vice president, international and China President at AstraZeneca, said: "Roxadustat's approval in China demonstrated the determination of the Chinese government in accelerating the supply of urgently needed new drugs to Chinese patients and supporting pharmaceutical innovation.

"In the future, AstraZeneca will work closely with the government to increase the accessibility of roxadustat in China and benefit more Chinese patients.

"At the same time, in response to the Chinese government's call for pharmaceutical innovation, we will build the local incubation platform to make more novel drugs benefiting Chinese patients first and open up China's pharmaceutical innovations to the world."

Chen Nan, a professor with Shanghai Jiao Tong University School of Medicine, who led principal investigator in the phase-three clinical trial of roxadustat in China, said: "Thanks to the improvement of China's pharmaceutical innovation atmosphere, Chinese researchers now have much better chance to show their excellence together with international peers, to further the global clinical development of first-in-class innovative drugs and to succeed in incubating them in China first.

"Our work is taking the lead not only in terms of speed, but also meets international standards in terms of quality, which demonstrates the research and development strength of China's healthcare professionals."

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 欧美成人午夜做爰视频在线观看 | 中文字幕成人在线 | 国产精品一区二区免费 | 男人又粗又硬桶女人免费 | 国产男人的天堂 | 丝袜毛片 | a级免费| 欧美aaaaa激情毛片 | 欧美一级日韩一级亚洲一级 | 看成年女人免费午夜视频 | 国产亚洲精品国产第一 | 久久精品视频网 | 思思久热re6这里有精品 | 一级片aaa| 全部免费毛片免费播放 | 国产高清免费视频 | 米奇777色狠狠8888影视 | 国产成人小视频在线观看 | videos欧美丰满肥婆 | 久久久久久久性高清毛片 | 成人欧美在线视频 | 久久999视频 | 18视频网站在线观看 | 四色永久 | 欧美黄色成人 | 成年网站视频在线观看 | 成人欧美视频在线看免费 | 日本三级香港三级妇三 | 久久亚洲欧美成人精品 | 久久国产精品成人免费 | 扒开双腿猛进入爽爽在线观看 | 男人一进一出桶女人视频 | 久久国产热视频 | 国产精品私人玩物在线观看 | 亚洲精品成人久久久影院 | 91资源在线播放 | 欧洲做人爱c欧美 | 国内精品一区二区在线观看 | 国产成人精品日本亚洲专一区 | 国产永久在线视频 | 成年男人的天堂 |